Weekly Investment Analysts’ Ratings Updates for Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has recently received a number of price target changes and ratings updates:

• 10/15/2026 – Arrowhead Pharmaceuticals is now covered by UBS Group AG. They set a “buy” rating and a $109.00 price target on the stock.
• 10/15/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $115.00 price target on the stock.
• 10/15/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
• 10/14/2026 – Arrowhead Pharmaceuticals was upgraded by UBS Group AG to “strong-buy”.
• 9/24/2026 – Arrowhead Pharmaceuticals is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $74.00 price target on the stock.
• 9/8/2026 – Arrowhead Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $108.00 price target on the stock.
• 9/1/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
• 8/31/2026 – Arrowhead Pharmaceuticals had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $100.00 price target on the stock.
• 8/31/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $115.00 price target on the stock.

Insider Activity

In related news, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is currently owned by corporate insiders.

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.